Search

SWG Educational Activities

Social and public activitiesSince 2020, Prof Hermann Einsele has been a Councilor to the EHA Board. Scientific activitiesFifth European CAR T-cell meetingDateFebruary 9–11, 2023. LocationRotterdam, The Netherlands.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

First CMML guidelines produced by EHA, now available

Dec 03 2018 Posted in Press releases Tagged CMML, Guidelines, HemaSphere, European Hematology Association, European LeukemiaNet

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.

COVID-19 – Impact on Childhood Hematology Patients

Wolfs, Tom F. W.